Recurrent SETD2 mutation in NPM1-mutated acute myeloid leukemia

Area of Science:

• Hematopoiesis
• Cancer Genomics
• Epigenetics

Background:

• SETD2 is the sole methyltransferase for H3K36me3, crucial for gene regulation.
• SETD2 loss-of-function mutations are found in Acute Myeloid Leukemia (AML).
• The specific role and distribution of SETD2 mutations in AML subtypes were previously unclear.

Discussion:

• NPM1 mutations frequently co-occur with SETD2 mutations in AML, more so than MLL rearrangements or AML1-ETO.
• Functional studies reveal SETD2 is essential for NPM1-mutated AML cell proliferation (OCI-AML3).
• SETD2's requirement for proliferation in NPM1-mutated AML contrasts with its established tumor suppressor role.

Key Insights:

• SETD2 maintains NPM1 expression in NPM1-mutated AML cells.
• SETD2 is dispensable for proliferation in MLL-rearranged AML cell lines (THP-1).
• SETD2 exhibits context-dependent functions in leukemogenesis.

Outlook:

• SETD2's opposing roles suggest subtype-specific functions in AML progression.
• Further research is needed to elucidate the dual nature of SETD2 in distinct AML contexts.
• Understanding SETD2's differential roles could inform targeted AML therapies.